{"organizations": [], "uuid": "f7172e560319e6bc9fdc4cce207c1586470f254d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-receives-sak/brief-caladrius-biosciences-receives-sakigake-expedited-review-designation-in-japan-for-clbs12-for-treating-critical-limb-ischemia-idUSFWN1RN0M8", "country": "US", "domain_rank": 408, "title": "BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T15:42:00.000+03:00", "replies_count": 0, "uuid": "f7172e560319e6bc9fdc4cce207c1586470f254d"}, "author": "", "url": "https://www.reuters.com/article/brief-caladrius-biosciences-receives-sak/brief-caladrius-biosciences-receives-sakigake-expedited-review-designation-in-japan-for-clbs12-for-treating-critical-limb-ischemia-idUSFWN1RN0M8", "ord_in_thread": 0, "title": "BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia", "locations": [], "entities": {"persons": [], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "brief-caladrius biosciences receives sakigake", "sentiment": "negative"}, {"name": "treating critical limb ischemia reuters", "sentiment": "none"}, {"name": "caladrius biosciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 42 PM / Updated 12 minutes ago BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia Reuters Staff 1 Min Read \nApril 10 (Reuters) - Caladrius Biosciences Inc: \n* CALADRIUS BIOSCIENCES RECEIVES SAKIGAKE EXPEDITED REVIEW DESIGNATION IN JAPAN FOR CLBS12 FOR TREATING CRITICAL LIMB ISCHEMIA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T15:42:00.000+03:00", "crawled": "2018-04-10T16:00:31.004+03:00", "highlightTitle": ""}